Immune checkpoint inhibitors in the onset of myasthenia gravis with hyperCKemia

Koutaro Takamatsu, Shunya Nakane, Shigeaki Suzuki, Takayuki Kosaka, Satoshi Fukushima, Toshihiro Kimura, Azusa Miyashita, Akihiro Mukaino, Shiori Yamakawa, Keisuke Watanabe, Masatoshi Jinnin, Yoshihiro Komohara, Hironobu Ihn, Yukio Ando

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Immune checkpoint inhibitors sometimes cause neuromuscular adverse events. Although a few cases of myasthenia gravis with hyperCKemia triggered by immune checkpoint inhibitors have been described, conclusive evidence remains limited. We conducted a systematic review of published cases of myasthenia gravis with hyperCKemia related to immune checkpoint inhibitors. Moreover, we tested anti-striational antibodies in the case of myasthenia gravis with myositis after nivolumab administration. We located 17 published case reports. Anti-striational antibodies were tested in six cases and five cases were positive. Our systematic analyses revealed poor prognosis in myasthenia gravis combined hyperCKemia with immune checkpoint inhibitors.

Original languageEnglish
JournalAnnals of Clinical and Translational Neurology
DOIs
Publication statusAccepted/In press - 2018 Jan 1

    Fingerprint

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology

Cite this

Takamatsu, K., Nakane, S., Suzuki, S., Kosaka, T., Fukushima, S., Kimura, T., Miyashita, A., Mukaino, A., Yamakawa, S., Watanabe, K., Jinnin, M., Komohara, Y., Ihn, H., & Ando, Y. (Accepted/In press). Immune checkpoint inhibitors in the onset of myasthenia gravis with hyperCKemia. Annals of Clinical and Translational Neurology. https://doi.org/10.1002/acn3.654